Xanomeline (LY246708)

Note:

This document is generated from content held within the Unified Studies Definitions Model. It is for test purposes only.

TEST DOCUMENT — TEST DOCUMENT — TEST DOCUMENT — Document doesn't look right? We'll help you out! — TEST DOCUMENT — TEST DOCUMENT — TE

Sponsor Confidentiality Statement:

Full Title:	Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease
Trial Acronym:	LZZT
Protocol Identifier:	H2Q-MC-LZZT
Original Protocol:	
Version Number:	2
Version Date:	2006-07-01
Amendment Identifier:	1
Amendment Scope:	Europe
Compound Codes(s):	
Compound Name(s):	
Trial Phase:	Phase II Trial
Short Title:	Xanomeline (LY246708)
Sponsor Name and Address:	Eli Lilly, Lilly Corporate Ctr, Indianapolis IN 4628 Denmark
Regulatory Agency Identifier Number(s):	NCT12345678
Spondor Approval Date:	2006-06-01

Note:

The table of contents is auto generated upon PDF production and only includes first level sections.

1 PROTOCOL SUMMARY

1.1 Protocol Synopsis

1.2 Trial Schema

1.3 Schedule of Activities

2 INTRODUCTION

2.1 Purpose of Trial

2.2 Summary of Benefits and Risks

3 TRIAL OBJECTIVES, ENDPOINTS AND ESTIMANDS

3.1 Primary Objectives

To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).	Alzheimer's Disease Assessment Scale - Cognitive Subscale, total of 11 items [ADAS-Cog (11)] at Week 24 Video-referenced Clinician's Interview-based Impression of Change (CIBIC+) at Week 24
To document the safety profile of the xanomeline TTS.	Adverse events Vital signs (weight, standing and supine blood pressure, heart rate) Laboratory evaluations (Change from Baseline)
To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas.	Alzheimer's Disease Assessment Scale - Cognitive Subscale, total of 11 items [ADAS-Cog (11)] at Weeks 8 and 16 Video-referenced Clinician's Interview-based Impression of Change (CIBIC+) at Weeks 8 and 16 Mean Revised Neuropsychiatric Inventory (NPI-X) from

To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).

To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).

To assess the treatment response as a function of Apo E genotype.

4 TRIAL DESIGN

4.1 Description of Trial Design

4.1.1 Participant Input into Design

4.2 Rationale for Trial Design

Previous studies of the oral formulation have shown that xanomeline tartrate may improve behavior and cognition. Effects on behavior are manifest within 2 to 4 weeks of initiation of treatment. The same studies have shown that 8 to 12 weeks are required to demonstrate effects on cognition and clinical global assessment. This study is intended to determine the acute and chronic effects of the TTS formulation in AD; for that reason, the study is of 26 weeks duration. Dosage specification has been made on the basis of tolerance to the xanomeline TTS in a clinical pharmacology study (H2Q-EW-LKAA), and target plasma levels as determined in studies of the oral formulation of xanomeline (H2Q-MC-LZZA).

4.2.1 Rationale for Comparator

The parallel dosing regimen maximizes the ability to make direct comparisons between the treatment groups. The use of placebo allows for a blinded, thus minimally biased, study. The placebo treatment group is a comparator group for efficacy and safety assessment.

Two interim analyses are planned for this study. The first interim analysis will occur when 50% of the patients have completed Visit 8 (8 weeks). If required, the second interim analysis will occur when 50% of the patients have completed Visit 12 (24 weeks).

4.2.2 Rationale for Adaptive or Novel Trial Design

4.2.3 Other Trial Design Considerations

4.3 Access to Trial Intervention After End of Trial

4.4 Start of Trial and End of Trial

5 TRIAL POPULATION

5.1 Selection of Trial Population

For Lilly studies, the following definitions are used:

Screen
Screening is the act of determining if an individual meets minimum requirements to become part of a pool of potential candidates for participation in a clinical study.

In this study, **screening** will include asking the candidate preliminary questions (such as age and general health status) and conducting invasive or diagnostic procedures and/or tests (for example, diagnostic psychological tests, x-rays, blood draws). Patients will sign the consent at their screening visit, thereby consenting to undergo the screening procedures and to participate in the study if they qualify.

To **enter**
Patients **entered** into the study are those from whom informed consent for the study has been obtained. Adverse events will be reported for each patient who has **entered** the study, even if the patient is never assigned to a treatment group (**enrolled**).

To **enroll**
Patients who are enrolled in the study are those who have been assigned to a treatment group. Patients who are entered into the study but fail to meet criteria specified in the protocol for treatment assignment will not be enrolled in the study.

At Visit 1, patients who meet the enrollment criteria of Mini-Mental State Examination (MMSE) score of 10 to 23 (Attachment LZZT.6), Hachinski Ischemia Score ≤4 (Attachment LZZT.8), a physical exam, safety labs, ECG, and urinalysis, will proceed to Visit 2 and Visit 3. At Visit 3, patients whose CNS imaging and other pending labs from Visit 1 satisfy the inclusion criteria (Section 3.4.2.1) will be enrolled in the study. Approximately 300 patients with a diagnosis of probable mild to moderate AD will be enrolled in the study.

5.2 Rationale for Trial Population

5.3 Inclusion Criteria

Patients may be included in the study only if they meet **all** the following criteria:

01
Males and postmenopausal females at least 50 years of age.

02
Diagnosis of probable AD as defined by National Institute of Neurological and

Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA) guidelines (Attachment LZZT.7).

03
MMSE score of 10 to 23.

04
Hachinski Ischemic Scale score of ≤4 (Attachment LZZT.8).

05
CNS imaging (CT scan or MRI of brain) compatible with AD within past 1 year.

The following findings are incompatible with AD:

a. Large vessel strokes

1. Any definite area of encephalomalacia consistent with ischemic necrosis in any cerebral artery territory.

2. Large, confluent areas of encephalomalacia in parieto-occipital or frontal regions consistent with watershed infarcts.

The above are exclusionary. Exceptions are made for small areas of cortical asymmetry which may represent a small cortical stroke or a focal area of atrophy provided there is no abnormal signal intensity in the immediately underlying parenchyma. Only one such questionable area allowed per scan, and size is restricted to ≤1cm in frontal/parietal/temporal cortices and ≤2 cm in occipital cortex.

- Small vessel ischemia

1. Lacunar infarct is defined as an area of abnormal intensity seen on CT scan or on both T1 and T2 weighted MRI images in the basal ganglia, thalamus or deep white matter which is ≤1 cm in maximal diameter. A maximum of one lacune is allowed per scan.

2. Leukoariosis or leukoencephalopathy is regarded as an abnormality seen on T2 but not T1 weighted MRIs, or on CT. This is accepted if mild or moderate in extent, meaning involvement of less than 25% of cortical white matter.

- Miscellaneous

1. Benign small extra-axial tumors (ie, meningiomas) are accepted if they do not contact or indent the brain parenchyma.

2. Small extra-axial arachnoid cysts are accepted if they do not indent or deform the brain parenchyma.

06
Investigator has obtained informed consent signed by the patient (and/or legal representative) and by the caregiver.

07
Geographic proximity to investigator's site that allows adequate follow-up.

08
A reliable caregiver who is in frequent or daily contact with the patient and who will accompany the patient to the office and/or be available by telephone at designated times, will monitor administration of prescribed medications, and will be responsible for the overall care of the patient at home. The caregiver and the patient must be able to communicate in English and willing to comply with 26 weeks of transdermal therapy.

5.4 Exclusion Criteria

Patients may be excluded in the study for **any** of the following reasons:

09
Persons who have previously completed or withdrawn from this study or any other study investigating xanomeline TTS or the oral formulation of xanomeline.

10
Use of any investigational agent or approved Alzheimer's therapeutic medication within 30 days prior to enrollment into the study.

11
Serious illness which required hospitalization within 3 months of screening.

12
Diagnosis of serious neurological conditions, including

a. a) Stroke or vascular dementia documented by clinical history and/or radiographic findings interpretable by the investigator as indicative of these disorders

- Seizure disorder other than simple childhood febrile seizures
- Severe head trauma resulting in protracted loss of consciousness within the last 5 years, or multiple episodes of head trauma
- Parkinson's disease

- Amyotrophic lateral sclerosis

- Myasthenia gravis.

13
Episode of depression meeting DSM-IV criteria within 3 months of screening.

14
A history within the last 5 years of the following:

a. a) Schizophrenia
b. b) Bipolar Disease
c. c) Ethanol or psychoactive drug abuse or dependence.

15
A history of syncope within the last 5 years.

16b
Evidence from ECG recording at screening of any of the following conditions :

a. a) Left bundle branch block
b. b) Bradycardia ≤50 beats per minute
c. c) Sinus pauses >2 seconds
d. d) Second or third degree heart block unless treated with a pacemaker
e. e) Wolff-Parkinson-White syndrome
f. f) Sustained supraventricular tachyarrhythmia including SVT≥10 sec, atrial fibrillation, atrial flutter.
g. g) Ventricular tachycardia at a rate of ≥120 beats per minute lasting
h. ≥10 seconds.

17
A history within the last 5 years of a serious cardiovascular disorder, including

a. a) Clinically significant arrhythmia
b. b) Symptomatic sick sinus syndrome not treated with a pacemaker
c. c) Congestive heart failure refractory to treatment

d. d) Angina except angina controlled with PRN nitroglycerin

e. e) Resting heart rate <50 or >100 beats per minute, on physical exam

f. f) Uncontrolled hypertension.

18
A history within the last 5 years of a serious gastrointestinal disorder, including

a. Chronic peptic/duodenal/gastric/esophageal ulcer that are untreated or refractory to treatment

b. Symptomatic diverticular disease

c. Inflammatory bowel disease

d. Pancreatitis

e. Hepatitis

f. Cirrhosis of the liver.

19
A history within the last 5 years of a serious endocrine disorder, including

a. Uncontrolled Insulin Dependent Diabetes Mellitus (IDDM)

b. Diabetic ketoacidosis

c. Untreated hyperthyroidism

d. Untreated hypothyroidism

e. Other untreated endocrinological disorder

20
A history within the last 5 years of a serious respiratory disorder, including

a. Asthma with bronchospasm refractory to treatment

b. Decompensated chronic obstructive pulmonary disease.

21
A history within the last 5 years of a serious genitourinary disorder, including

a. Renal failure

b. Uncontrolled urinary retention

22

a. Lupus

b. Temporal arteritis

c. Severe rheumatoid arthritis.

23

A known history of human immunodeficiency virus (HIV) within the last 5 years.

24

A history within the last 5 years of a serious infectious disease including

a. a) Neurosyphilis

b. b) Meningitis

c. c) Encephalitis.

25

A history within the last 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal PSA postresection.

26

Visual, hearing, or communication disabilities impairing the ability to participate in the study; (for example, inability to speak or understand English, illiteracy).

27b

[Laboratory test values exceeding the Lilly Reference Range III for the patient's age in any of the following analytes: ↑ creatinine, ↑ total bilirubin, ↑ SGOT, ↑ SGPT, ↑ alkaline phosphatase, ↑ GGT, ↑↓ hemoglobin, ↑↓ white blood cell count, ↑↓ platelet count, ↑↓ serum sodium, potassium, or calcium.

If values exceed these laboratory reference ranges, clinical significance will be judged by the monitoring physicians. If the monitoring physician determines that the deviation from the reference range is not clinically significant, the patient may be included in the study. This decision will be documented.

28b

Central laboratory test values below reference range for folate, and Vitamin B 12 , and outside reference range for thyroid function tests.

a. Folate reference range 2.0 to 25.0 ng/mL. Patients will be allowed to enroll if

taking vitamin supplements

b. Vitamin B 12 reference range 130 to 900 pg/mL. Patients will be allowed to enroll if their B 12 levels are above the upper reference range if patients are taking oral vitamin supplements.

c. Thyroid functions

    i. Thyroid Uptake reference range 25 to 38%. Patients will be allowed to enroll with results of 23 to 51% provided the remainder of the thyroid profile is normal and there are no clinical signs or symptoms of thyroid abnormality.

    ii. TSH reference range 0.32 to 5.0. Patients will be allowed to enroll with results of 0.03 to 6.2 if patients are taking stable doses of exogenous thyroid supplements, with normal free thyroid index, and show no clinical signs or symptoms of thyroid abnormality.

    iii. Total T4 reference range 4.5 to 12.5. Patients will be allowed to enroll with results of 4.1 to 13.4 if patients are taking stable doses of exogenous thyroid hormone, with normal free thyroid index, and show no clinical signs or symptoms of thyroid abnormality.

    iv. Free Thyroid Index reference range 1.1 to 4.6.

Treatment with the following medications within the specified washout periods prior to enrollment and during the study:

a. Anticonvulsants including but not limited to

Depakote® (valproic acid)	2 weeks
Dilantin® (phenytoin)	2 weeks
Felbatol® (felbamate)	1 month
Klonopin® (clonazepam)	2 weeks
Lamictal® (lamotrigine)	2 weeks
Mysoline® (primidone)	1 month

Neurontin® (gabapentin)	2 weeks
Phenobarbitol	1 month
Tegretol® (carbamazepine)	2 weeks

b. Alpha receptor blockers including but not limited to

Aldomet® (methyldopa)	2 weeks
Cardura® (doxazosin)	2 weeks
Catapres® (clonidine)	2 weeks
Hytrin® (terazosin)	2 weeks
Minipress® (prazosin)	2 weeks
Tenex® (guanfacine)	2 weeks
Wytensin® (guanabenz)	2 weeks

The use of low doses (2 mg daily) of either Hytrin® or Cardura® for relief of urinary retention for patients with prostatic hypertrophy will be considered on a case-by-case basis provided blood pressure is stable and the medication has not had demonstrable effect on dementia symptoms in the opinion of the treating physician. Contact CRO medical monitor.

c. Calcium channel blockers that are CNS active including but not limited to

Calan® , Isoptin® , Verelan® (verapamil)	2 weeks
Cardizem® (diltiazem)	2 weeks
Nimotop® (nimodipine)	2 weeks
Adalat® , Procardia XL® (nifedipine)	2 weeks

Cardene® (nicardipine), Norvasc® , (amlodipine), and DynaCirc® (isradipine) will be allowed during the study. If a patient is taking an excluded calcium channel blocker and is changed to an equivalent dose of an allowed calcium channel blocker, enrollment may proceed in a

little as 24 hours though 1 week is preferred when possible

d. Beta blockers including but not limited to

Betapace® (sotalol)	2 weeks
Inderal® (propranolol)	2 weeks
Lopressor® , Toprol XL® (metoprolol)	2 weeks
Corgard® (nadolol)	2 weeks
Sectral® (acebutolol)	2 weeks
Tenormin® (atenolol)	2 weeks
Visken® (pindolol)	2 weeks

Beta blocker eye drops for glaucoma will be considered on a case-by-case basis. Call medical monitor.

e. Beta sympathomimetics (unless inhaled) including but not limited to

Alupent® tablets (metaproterenol)	2 weeks
Brethine® tablets (terbutaline)	2 weeks
Dopamine	2 weeks
Proventil Repetabs® , Ventolin® tablets (albuterol tablets)	2 weeks

f. Parasympathomimetics (cholinergics) (unless opthalmic) including but not limited to

Antilirium® (physostigmine)	1 month
Aricept® (donepezil)	1 month
Cognex® (tacrine)	1 month
Mestinon® (pyridostigmine)	1 week
Reglan® (metoclopramide)	2 weeks
Urecholine® , Duvoid (bethanechol)	2 weeks

Cholinergic eye drops for treatment of glaucoma will be allowed during the study on a case-by-case basis. Please contact the CRO medical monitor.

g. Muscle relaxants-centrally active including but not limited to

Equanil® (meprobamate)	2 weeks
Flexeril® (cyclobenzaprine)	2 weeks
Lioresal® (baclofen)	2 weeks
Norflex® (orphenadrine)	2 weeks
Parafon Forte® (chlorzoxazone)	2 weeks
Robaxin® (methocarbamol)	2 weeks
Skelaxin® (metaxalone)	2 weeks
Soma® (carisoprodol)	2 weeks

h. Monamine oxidase inhibitors (MAOI) including but not limited to

Eldepryl® (selegiline)	1 month
Nardil® (phenelzine)	1 month
Parnate® (tranylcypromine)	1 month

i. Parasympatholytics including but not limited to

Antivert® , Bonine® , Dramamine II® (meclizine)	3 days
Artane® (trihexyphenidyl)	2 weeks
Bellergal-S® (alkaloids of belladonna and ergotamine)	2 weeks
Bentyl® (dicyclomine)	3 days
Cogentin® (benztropine)	2

	weeks
Cystospaz® , Levsin® , Levsinex® (hyoscyamine)	2 weeks
Ditropan® (oxybutynin)	2 weeks
Donnatal® , Hyosophen® (atropine, scopolamine, hyoscyamine and phenobarbitol)	1 month
Dramamine® (dimenhydrinate)	3 days
Lomotil® , Lonox® (atropine, diphenoxylate)	2 weeks
Pro-Banthine® (propantheline)	2 weeks
Robinul® (glycopyrrolate)	3 days
Tigan® (trimethobenzamide)	3 days
Transderm-Scop® (scopolamine)	2 weeks
Urispas® (flavoxate) 2 weeks	

j. Antidepressants including but not limited to

Anafranil® (clomipramine)	1 month
Asendin® (amoxapine)	1 month
Desyrel® (trazodone)	1 month
Effexor® (venlafaxine)	1 month
Elavil® (amitriptyline)	1 month
Ludiomil® (maprotiline)	1 month
Norpramin® (desipramine)	1 month

Pamelor® , Aventyl® (nortriptyline)	1 month
Paxil® (paroxetine)	1 month
Prozac® (fluoxetine	1 month
Remeron® (mirtazapine)	1 month
Serzone® (nefazodone)	1 month
Sinequan® (doxepin)	1 month
Tofranil® (imipramine)	1 month
Vivactil® (protriptyline)	1 month
Wellbutrin® (bupropion)	1 month
Zoloft® (sertraline)	1 month

k. Systemic corticosteroids including but not limited to

Cortisone	2 weeks
Decadron® (dexamethasone)	2 weeks
Depo-Medrol® (methylprednisolone)	1 month
Prednisone	2 weeks

l. Xanthine derivatives including but not limited to

Aminophylline	2 weeks
Fioricet® , Esgic® , Phrenilin Forte® (caffeine, butalbital)	3 days
Theo-Dur® (theophylline)	2 weeks
Wigraine® , Cafergot® (caffeine, ergotamine)	3 days

m. Histamine (H2) antagonists including but not limited to

Axid® (nizatidine)	1 week

Pepcid® (famotidine)	1 week
Tagamet® (cimetidine)	1 week
Zantac® (ranitidine)	1 week

If an H 2 antagonist is needed by the patient, Axid® will be allowed on a case-by-case basis. Please consult CRO medical monitor.

n. Narcotic Analgesics including but not limited to

Darvocet-N 100® , (propoxyphene)	1 week
Demerol® (meperidine)	1 week
Dilaudid® (hydromorphone)	1 week
Duragesic® (fentanyl)	1 week
MS Contin® , Roxanol® , Oramorph® (morphine)	1 week
Percocet® , Roxicet® (oxycodone with acetaminophen)	3 days
Percodan® , Roxiprin	1 week
Stadol® (butorphanol)	1 week
Talacen® (pentazocine)	1 week
Tylenol #2® , #3® , #4® (codeine and acetaminophen)	3 days
Tylox® , Roxilox® (oxycodone)	3 days
Vicodin® , Lorcet® (hydrocodone)	1 week

Percocet (oxycodone with acetaminophen) and Tylenol® with codeine #2, #3, #4 (acetaminophen + codeine) ARE allowed in the month prior to enrollment, but are not permitted in the 3 days prior to enrollment.

o. Neuroleptics (antipsychotics) including but not limited to

Clozaril® (clozapine)	2 weeks
Haldol® (haloperidol)	2 weeks

Loxitane® (loxapine)	2 weeks
Mellaril® (thioridazine)	2 weeks
Moban® (molindone)	2 weeks
Navane® (thiothixene)	2 weeks
Orap® (pimozide)	2 weeks
Prolixin® (fluphenazine)	1 month
Risperdal® (risperidone)	2 weeks
Stelazine® (trifluoperazine)	2 weeks
Thorazine® (chlorpromazine)	2 weeks
Trilafon® (perphenazine)	2 weeks
Serentil® (mesoridazine)	2 weeks

The use of neuroleptics on a daily basis must be discontinued 2 to 4 weeks prior to enrollment. The use of neuroleptics on an as-needed basis is allowable during the screening period, but the last dose must be at least 7 days prior to enrollment.

p. Antianxiety agents including but not limited to

Atarax® (hydroxyzine)	2 weeks
BuSpar® (buspirone)	2 weeks
Librium® (chlordiazepoxide)	2 weeks
Serax® (oxazepam)	2 weeks
Tranxene® (clorazepate)	2 weeks
Valium® (diazepam)	2 weeks
Vistaril® (hydroxyzine pamoate)	2 weeks
Xanax® (alprazolam)	2 weeks

Ativan® (lorazepam) should be discontinued on a daily basis 2 weeks prior to enrollment. It may be used on an as-needed basis during the screening period, but is not permitted in the 24 hours prior to enrollment.

q. Hypnotics/Sedatives including but not limited to

Ambien® (zolpidem)	3 days
Dalmane® (flurazepam)	3 days
Doral® (quazepam)	3 days
Halcion® (triazolam)	3 days
Nembutal®	2 weeks
ProSom® (estazolam)	3 days
Restoril® (temazepam)	3 days
Seconal®	2 weeks

Chloral Hydrate is allowed on an as-needed basis during screening, but is not permitted in the 24 hours prior to enrollment.

r. Histamine (H1) antagonists including but not limited to

Actifed® , Actifed Plus® (triprolidine) Benadryl® , Unisom® , Tylenol P.M.®	3 days
(diphenhydramine)	3 days
Compazine® (prochlorperazine)	3 days
Contac® , Coricidin D® , Sinutab® , Novahistine® , Alka Seltzer Plus® , Naldecon® , Sudafed Plus® , Tylenol Cold® , Tylenol Cold and Flu® (chlorpheniramine)	3 days
Dimetapp® (brompheniramine)	3

	days
Drixoral® (dexbrompheniramine)	3 days
Hismanal® (astemizole)	1 week
Phenergan® (promethazine)	3 days
Seldane® (terfenadine)	1 week
Tavist® (clemastine fumarate)	3 days
Zyrtec® (cetrizine)	1 week

Allegra® (fexofenadine hydrochloride) or Claritin® (loratadine) may be taken on as-needed basis during screening but must be discontinued within 24 hours of enrollment.

s. Stimulants including but not limited to

Cylert® (pemoline)	1 month
Ritalin® (methylphenidate)	1 month

t. Antiarrhythmics including but not limited to the following

Adenocard® (adenosine)
Cordarone® (amiodarone)
Ethmozine® (moricizine)
Mexitil® (mexiletine)
Norpace® (disopyramide)
Procan® (procainamide)

Quinaglute® (quinidine)
Rythmol® (propafenone)
Tambocor® (flecainide)
Tonocard® (tocainide)

Requirement of these drugs for control of cardiac arrhythmia indicates that the patient should be excluded from the study. If discontinuation of an antiarrhythmic is considered, please discuss case with CRO medical monitor.

u. Miscellaneous drugs including but not limited to

Coenzyme Q	2 weeks
Eskalith® , Lithobid® (lithium)	2 weeks
Ginkgo biloba	1 week
Lecithin	1 week
Lecithin	1 week
Lupron	2 weeks
Tamoxifen	1 month

v. Estrogen supplements are permitted during the study, but dosage must be stable for at least 3 months prior to enrollment.

29b
Positive syphilis screening.

Positive syphilis screening. As determined by positive RPR followed up by confirmatory FTA-Abs. Confirmed patients are excluded unless there is a documented medical history of an alternative disease (for example, yaws) which caused the lab abnormality.

30b
Glycosylated hemoglobin (A1C). Required only on patients with known diabetes mellitus or random blood sugar >200 on screening labs. Patients will be excluded if levels are >9.5%

31b

Glycosylated hemoglobin (HgA1c) required only in non-diabetic patients

or random blood sugar >200 on screening labs. Patients will be excluded if levels are >9.5%

5.5 Lifestyle Considerations

5.5.1 Meals and Dietary Restrictions

5.5.2 Caffeine, Alcohol, Tobacco, and Other Habits

Not applicable

5.5.3 Physical Activity

5.5.4 Other Activity

5.6 Screen Failures

6 TRIAL INTERVENTION AND CONCOMITANT THERAPY

6.1 Description of Trial Intervention

6.2 Rationale for Trial Intervention

6.3 Dosing and Administration

6.3.1 Trial Intervention Dose Modification

6.4 Treatment of Overdose

6.5 Preparation, Handling, Storage and Accountability

6.5.1 Preparation of Trial Intervention

6.5.2 Handling and Storage of Trial Intervention

6.5.3 Accountability of Trial Intervention

6.6 Participant Assignment, Randomisation and Blinding

6.6.1 Participant Assignment

6.6.2 Randomisation

6.6.3 Blinding and Unblinding

The study will be double-blind. To further preserve the blinding of the study, only a minimum number of Lilly and CRO personnel will see the randomization table and codes before the study is complete.

Emergency codes generated by a computer drug-labeling system will be available to the investigator. These codes, which reveal the patients treatment group, may be opened during the study only if the choice of follow-up treatment depends on the patient's therapy assignment.

The investigator should make every effort to contact the clinical research physician prior to unblinding a patient's therapy assignment. If a patient's therapy assignment is unblinded, Lilly must be notified immediately by telephone. After the study, the investigator must return all sealed and any opened codes.

6.7 Treatment Compliance

6.8 Concomitant Therapy

6.8.1 Prohibited Concomitant Therapy

6.8.2 Permitted Concomitant Therapy

6.8.3 Rescue Therapy

6.8.4 Other Therapy

7 DISCONTINUATION OF TRIAL INTERVENTION AND PARTICIPANT WITHDRAWAL FROM TRIAL

7.1 Discontinuation of Trial Intervention

7.1.1 Criteria for Permanent Discontinuation of Trial Intervention

7.1.2 Temporary Discontinuation or Interruption of Trial Intervention

7.1.3 Rechallenge

7.2 Participant Withdrawal from the Trial

7.3 Lost to Follow-Up

7.4 Trial Stopping Rules

8 TRIAL ASSESSMENTS AND PROCEDURES

8.1 Screening/Baseline Assessments and Procedures

8.2 Efficacy Assessments and Procedures

8.3 Safety Assessments and Procedures

8.3.1 Physical Examination

8.3.2 Vital Signs

8.3.3 Electrocardiograms

8.3.4 Clinical Laboratory Assessments

8.3.5 Suicidal Ideation and Behaviour Risk Monitoring

8.4 Adverse Events and Serious Adverse Events

8.4.1 Definitions of AE and SAE

8.4.2 Time Period and Frequency for Collecting AE and SAE Information

8.4.3 Identifying AEs and SAEs

8.4.4 Recording of AEs and SAEs

8.4.5 Follow-up of AEs and SAEs

8.4.6 Reporting of SAEs

8.4.7 Regulatory Reporting Requirements for SAEs

8.4.8 Serious and Unexpected Adverse Reaction Reporting

8.4.9 Adverse Events of Special Interest

8.4.10 Disease-related Events or Outcomes Not Qualifying as AEs or SAEs

8.5 Pregnancy and Postpartum Information

8.5.1 Participants Who Become Pregnant During the Trial

8.5.2 Participants Whose Partners Become Pregnant

8.6 Medical Device Product Complaints for Drug / Device Combination Products

8.6.1 Definition of Medical Device Product Complaints

8.6.2 Recording of Medical Device Product Complaints

8.6.3 Time Period and Frequency for Collecting Medical Device Product Complaints .

8.6.4 Follow-Up of Medical Device Product Complaints

8.6.5 Regulatory Reporting Requirements for Medical Device Product Complaints

8.7 Pharmacokinetics

8.8 Genetics

8.9 Biomarkers

8.1 Immunogenicity Assessments

8.1.1 Medical Resource Utilisation and Health Economics

9 STATISTICAL CONSIDERATIONS

10 GENERAL CONSIDERATIONS: REGULATORY, ETHICAL, AND TRIAL OVERSIGHT

10.1 Regulatory and Ethical Considerations

10.2 Committees

10.3 Informed Consent Process

10.4 Data Protection

10.5 Early Site Closure or Trial Termination

11 GENERAL CONSIDERATIONS: RISK MANAGEMENT AND QUALITY ASSURANCE

11.1 Quality Tolerance Limits

11.2 Data Quality Assurance

11.3 Source Data

TEST DOCUMENT — TEST DOCUMENT — TEST DOCUMENT — Document doesn't look right? We'll help you out! — TEST DOCUMENT — TEST DOCUMENT — TE

12 APPENDIX: ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS - DEFINITIONS, SEVERITY, AND CAUSALITY

12.1 Further Details and Clarifications on the AE Definition

12.2 Further Details and Clarifications on the SAE Definition

12.3 Severity

12.4 Causality

13 APPENDIX: DEFINITIONS AND SUPPORTING OPERATIONAL DETAILS

13.1 Contraception and Pregnancy Testing

13.1.1 Definitions Related to Childbearing Potential

13.1.2 Contraception

13.1.3 Pregnancy Testing

13.2 Clinical Laboratory Tests

13.3 Country/Region-Specific Differences

13.4 Prior Protocol Amendments

14 APPENDIX: GLOSSARY OF TERMS

15 APPENDIX: REFERENCES

TEST DOCUMENT — TEST DOCUMENT — TEST DOCUMENT — Document doesn't look right? We'll help you out! — TEST DOCUMENT — TEST DOCUMENT — TE